NCT06674785 SIRS-ESWT Trial: Shoulder Internal Rotator Spasticity Trial Treated With Extracorporeal Shock Wave Therapy Trial
| NCT ID | NCT06674785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-23 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-23 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Extracorporeal shock wave therapy (ESWT) has shown potential in reducing post-stroke limb spasticity. This study aims to evaluate the efficacy of focused ESWT on shoulder internal rotator spasticity in post-stroke patients.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older with unilateral cerebral stroke. * Restricted passive external rotation of the spastic shoulder by more than 20 degrees. * A Modified Ashworth Scale score of 1 or higher for shoulder internal rotator spasticity. * Stable medical condition and vital signs. * Clear consciousness, able to follow instructions. Exclusion Criteria: * History of two or more strokes, traumatic brain injury, brain tumors, or other cerebral disorders. * Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal conditions affecting muscle tone assessment. * Ineligibility for shock wave intervention due to malignancies, coagulation disorders, localized infections, or presence of a pacemaker. * Prior shock wave intervention or botulinum toxin injection for post-stroke spasticity within the past three months. * Inability to participate in interventions or functional assessments due to cognitive, consciousness, or language impairments.
Contact & Investigator
Shu-mei Yang, MD
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT06674785 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06674785 currently recruiting?
Yes, NCT06674785 is actively recruiting participants. Contact the research team at b99401109@gmail.com for enrollment information.
Where is the NCT06674785 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06674785 clinical trial?
NCT06674785 is sponsored by National Taiwan University Hospital. The principal investigator is Shu-mei Yang, MD at National Taiwan University Hospital. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.